|
|
|
| Superiority comparison of single-pill combination and traditional antihypertensive strategies#br# |
| WANG Ruxian DAI Qingyuan▲ |
| Department of Cardiology, First Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650032, China |
|
|
|
Abstract Hypertension is a chronic disease with a high degree of morbidity, and a major risk factor for cardiovascular and cerebrovascular diseases. The treatment and management of hypertension have always been problems in China and even in the world. Countries around the world also have been searching for treatment methods to rapidly decrease blood pressure and maintain long-term stable blood pressure, from traditional antihypertensive strategies such as monotherapy, ladder treatment, free combination treatment to single-pill combination (SPC), which has emerged in recent years. SPC is composed of two or more drugs with different antihypertensive mechanism, which is the optimization and extension of combination treatment. The superior hypotensive ability of SPC has been widely verified in clinical trials, SPC has a stronger hypotensive effect, a higher compliance rate of blood pressure and an earlier time of compliance than the three traditional antihypertensive strategies mentioned above, it has a better application prospect in the treatment and management of hypertension.
|
|
|
|
|
|
[1] Wang ZW，Chen Z，Zhang LF，et al. Status of Hypertension in China：Results From the China Hypertension Survey，2012-2015 [J]. Circulation，2018，137（22）：2344-2356.
[2] 高血压联盟（中国），中国医疗保健国际交流促进会高血压分会，中国高血压防治指南修订委员会，等.中国高血压防治指南（2018年修订版）[J].中国心血管杂志，2019， 24（1）：33.
[3] Unger T，Borghi C，Charchar F，et al. 2020 International Society of Hypertension global hypertension practice guidelines [J]. J Hypertens，2020，38（6）：982-1004.
[4] Williams B，Mancia G，Spiering W，et al. 2018 ESC/ESH guidelines for the management of arterial hypertension [J]. Eur Heart J，2018，39（33）：3021-3104.
[5] 王文.多重机制互补，联合优效降压——关注新型单片复方制剂[J].中华高血压杂志，2014，22（9）：820-823.
[6] 吴玮芳，陈宝军，王丹丹.固定单片复方制剂治疗高血压的研究进展[J].中国临床药学杂志，2015，24（5）：335-338.
[7] 赵林双.从2019美国糖尿病协会指南看单片复方制剂的优化应用[J].中华高血压杂志，2019，27（9）：814-816.
[8] Lopatowska P，Mlodawska E，Tomaszuk-Kazberuk A，et al. Adhering to the principles of clinical pharmacology-the correct fixed combinations of antihypertensive drugs [J]. Expert Rev Clin Pharmacol，2018，11（2）：165-170.
[9] Tamargo J，Duarte J，Ruilope LM. New antihypertensive drugs under development [J]. Curr Med Chem，2015，22：305-342.
[10] 陈鲁原.高血压药物治疗原则及优化[J].中国实用内科杂志，2019，39（1）：19-22.
[11] 赵连友.重视个体化联合用药治疗高血压的临床价值[J].中国实用内科杂志，2019，39（1）：1-4.
[12] Egan BM，Bandyopadhyay D，Shaftman SR，et al. Initial monotherapy and combination therapy and hypertension control the first year [J]. Hypertension，2012，59（6）：1124-1131.
[13] 王琼.单片复方制剂在高血压治疗中的优势：从降压到降低心血管事件风险[J].中华高血压杂志，2016，24（1）：15-18.
[14] 柯元南，黄峻，诸骏仁.缬沙坦/氨氯地平复方片剂对单药控制不良的轻中度高血压患者的疗效观察[J].中华心血管病杂志，2009，37（9）：794-799.
[15] Wang JG，Zeng WF，He YS，et al. Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy [J]. Adv Ther，2013，30（8）：771-783.
[16] Zhu DL，Gao PJ，Liu SW，et al. Efficacy and tolerability of a single-pill combination of telmisartan/ hydrochlorothiazide 80/25mg in Chinese and Korean patients with moderate to severe hypertension：a subgroup analysis of a randomized，double-blind，active-controlled trial [J]. Chin Med J，2013，126（21）：4072-4077.
[17] Laurent S，Mancia G，Poulter N. Perindopril 3.5mg/ amlodipine 2.5mg versus renin-angiotensin system inhibitor monotherapy as first-line treatment in hypertension： a combined analysis [J]. J Hypertens，2018，36（9）：1915-1920.
[18] Feldman RD，Zou GY，Vandervoort MK，et al. A simplified approach to the treatment of uncomplicated hypertension： a cluster randomized， controlled trial [J]. Hypertension，2009，53（4）：646-653.
[19] Chang J，Yang W，Fellers T，et al. Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement [J]. Curr Med Res Opin，2010，26（9）：2203-2212.
[20] Weisser B，Predel HG，Gillessen A，et al. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia：Results of a Meta-Analysis [J]. High Blood Press Cardiovasc Prev，2020，27（2）：157-164.
[21] Mazza A，Lenti S，Schiavon L，et al. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control： From Clinical Trials to Clinical Practice [J]. Adv Ther，2017，34（4）：975-985.
[22] Mourad JJ，Waeber B，Zannad F，et al. Comparison of different therapeutic strategies in hypertension：a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach [J]. J Hypertens，2004，22（12）：2379-2386.
[23] Lacourcière Y，Poirier L，Lefebvre J. Expedited blood pressure control with initial angiotensin Ⅱ antagonist /diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension [J]. Can J Cardiol，2007，23（5）：377-382.
[24] Mancia G，Asmar R，Amodeo C，et al. Comparison of single-pill strategies first line in hypertension：perindopril/amlodipine versus valsartan / amlodipine [J]. J Hypertens，2015，33（2）：401-411.
[25] 韩学芳，袁若雯，张盼盼，等.高血压患者血压早期达标的研究进展[J].医学综述，2019，25（5）：934-938，945.
[26] 喜杨，陈源源.单片复方制剂降压药物在基层医疗机构中的临床应用专家建议[J].中华老年心脑血管病杂志，2020，22（8）：810-815.
[27] Lasserson DS，Buclin T，Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data [J]. Heart，2011，97（21）：1771-1775.
[28] 《单片复方制剂降压治疗中国专家共识》专家组，中华医学会心血管病学分会高血压学组.单片复方制剂降压治疗中国专家共识[J].中华高血压杂志，2019，27（4）：310-317. |
|
|
|
